ABIOMED logoABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:ABMD
  • CUSIP: 00365410
  • Web: www.abiomed.com
  • Market Cap: $7.61 billion
  • Outstanding Shares: 44,102,000
Average Prices:
  • 50 Day Moving Avg: $161.28
  • 200 Day Moving Avg: $144.70
  • 52 Week Range: $95.14 - $175.71
  • Trailing P/E Ratio: 100.86
  • Foreward P/E Ratio: 65.08
  • P/E Growth: 2.76
Sales & Book Value:
  • Annual Revenue: $474.78 million
  • Price / Sales: 16.02
  • Book Value: $12.86 per share
  • Price / Book: 13.41
  • EBITDA: $110.92 million
  • Net Margins: 16.13%
  • Return on Equity: 13.03%
  • Return on Assets: 10.98%
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 5.95%
  • Quick Ratio: 5.32%
  • Average Volume: 309,364 shs.
  • Beta: 0.26
  • Short Ratio: 4.61

Frequently Asked Questions for ABIOMED (NASDAQ:ABMD)

What is ABIOMED's stock symbol?

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

How were ABIOMED's earnings last quarter?

ABIOMED, Inc. (NASDAQ:ABMD) released its earnings results on Thursday, July, 27th. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.42 by $0.03. The business earned $132.47 million during the quarter, compared to analysts' expectations of $130.83 million. ABIOMED had a return on equity of 13.03% and a net margin of 16.13%. The firm's revenue was up 28.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.29 earnings per share. View ABIOMED's Earnings History.

When will ABIOMED make its next earnings announcement?

ABIOMED is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for ABIOMED.

Where is ABIOMED's stock going? Where will ABIOMED's stock price be in 2017?

8 equities research analysts have issued 12 month target prices for ABIOMED's stock. Their predictions range from $140.00 to $208.00. On average, they anticipate ABIOMED's stock price to reach $174.71 in the next year. View Analyst Ratings for ABIOMED.

Who are some of ABIOMED's key competitors?

Who are ABIOMED's key executives?

ABIOMED's management team includes the folowing people:

  • Michael R. Minogue, Chairman of the Board, President, Chief Executive Officer
  • Ian McLeod, Principal Financial Officer, Principal Accounting Officer, Vice President, Controller
  • David M. Weber, Chief Operating Officer
  • William J. Bolt, Senior Vice President, Global Quality, Regulatory and Clinical Operations
  • Andrew J. Greenfield, Vice President, General Manager - Global Marketing
  • Michael G. Howley, Vice President, General Manager - Global Sales and Marketing
  • Dorothy E. Puhy, Lead Independent Director
  • Jeannine M. Rivet, Independent Director
  • Eric A. Rose M.D., Independent Director
  • Martin P. Sutter, Independent Director

Who owns ABIOMED stock?

ABIOMED's stock is owned by many different of institutional and retail investors. Top institutional shareholders include PRIMECAP MANAGEMENT COMPANY (9.85%) and Eqis Capital Management Inc. (0.00%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.

Who sold ABIOMED stock? Who is selling ABIOMED stock?

ABIOMED's stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. Company insiders that have sold ABIOMED stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Michael G Howley and Paul Thomas. View Insider Buying and Selling for ABIOMED.

How do I buy ABIOMED stock?

Shares of ABIOMED can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ABIOMED's stock price today?

One share of ABIOMED stock can currently be purchased for approximately $172.47.

MarketBeat Community Rating for ABIOMED (NASDAQ ABMD)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  269 (Vote Outperform)
Underperform Votes:  189 (Vote Underperform)
Total Votes:  458
MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ABIOMED (NASDAQ:ABMD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $174.71 (1.30% upside)
Consensus Price Target History for ABIOMED (NASDAQ:ABMD)
Price Target History for ABIOMED (NASDAQ:ABMD)
Analysts' Ratings History for ABIOMED (NASDAQ:ABMD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
10/12/2017Leerink SwannReiterated RatingOutperform$180.00 -> $200.00N/AView Rating Details
9/29/2017SunTrust Banks, Inc.Initiated CoverageBuy -> Buy$195.00HighView Rating Details
9/29/2017Jefferies Group LLCBoost Price TargetBuy$175.00 -> $208.00HighView Rating Details
8/29/2017Piper Jaffray CompaniesReiterated RatingBuy$160.00LowView Rating Details
7/10/2017Morgan StanleyReiterated RatingEqual Weight$135.00 -> $140.00LowView Rating Details
6/8/2017William BlairReiterated RatingOutperform -> OutperformLowView Rating Details
12/6/2016GuggenheimInitiated CoverageBuy$150.00N/AView Rating Details
4/10/2016Benchmark Co.Reiterated RatingBuy$145.00N/AView Rating Details
10/30/2015Raymond James Financial, Inc.UpgradeMarket Perform -> Outperform$85.00N/AView Rating Details
10/29/2015Sterne Agee CRTReiterated RatingBuyN/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for ABIOMED (NASDAQ:ABMD)
Earnings by Quarter for ABIOMED (NASDAQ:ABMD)
Earnings History by Quarter for ABIOMED (NASDAQ ABMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017$0.36N/AView Earnings Details
7/27/2017Q1 2018$0.42$0.45$130.83 million$132.47 millionViewN/AView Earnings Details
5/4/2017Q4 2017$0.33$0.33$122.82 million$124.68 millionViewListenView Earnings Details
1/26/2017Q317$0.29$0.34$112.71 million$114.70 millionViewListenView Earnings Details
10/27/2016Q217$0.24$0.20$103.16 million$103.00 millionViewListenView Earnings Details
7/28/2016Q117$0.23$0.29$97.23 million$103.00 millionViewListenView Earnings Details
5/3/2016Q416$0.19$0.24$90.52 million$94.00 millionViewN/AView Earnings Details
2/4/2016Q316$0.15$0.23$80.04 million$85.80 millionViewListenView Earnings Details
10/29/2015Q2$0.13$0.17$74.56 million$76.30 millionViewListenView Earnings Details
8/4/2015Q116$0.08$0.20$66.27 million$73.40 millionViewN/AView Earnings Details
5/5/2015Q415$0.12$0.28$62.55 million$67.60 millionViewN/AView Earnings Details
1/27/2015Q315$0.03$0.30$53.20 million$62.00 millionViewN/AView Earnings Details
10/30/2014Q215$0.02$0.09$48.80 million$51.80 millionViewN/AView Earnings Details
7/31/2014Q115$0.02($0.04)$297.10 million$48.80 millionViewN/AView Earnings Details
5/1/2014Q414$0.09$0.09$50.93 million$50.40 millionViewN/AView Earnings Details
1/31/2014Q314$0.05$0.11$46.00 million$46.20 millionViewN/AView Earnings Details
11/6/2013Q214$0.03$0.03$43.75 million$44.30 millionViewN/AView Earnings Details
8/1/2013Q1 2014$0.06($0.04)$42.93 million$42.70 millionViewN/AView Earnings Details
5/2/2013Q4 2013$0.08$0.09$41.87 million$43.70 millionViewN/AView Earnings Details
2/6/2013Q3 2013$0.07$0.07$38.04 million$38.30 millionViewN/AView Earnings Details
11/1/2012Q213$0.05$0.20$37.47 million$37.40 millionViewN/AView Earnings Details
8/2/2012$0.10$0.16ViewN/AView Earnings Details
5/16/2012$0.07$0.07ViewN/AView Earnings Details
2/3/2012($0.01)$0.07ViewN/AView Earnings Details
11/3/2011($0.09)$0.02ViewN/AView Earnings Details
8/4/2011($0.06)($0.03)ViewN/AView Earnings Details
5/18/2011($0.04)($0.05)ViewN/AView Earnings Details
2/3/2011($0.09)($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ABIOMED (NASDAQ:ABMD)
2017 EPS Consensus Estimate: $1.09
2018 EPS Consensus Estimate: $1.78
2019 EPS Consensus Estimate: $2.47
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20176$0.20$0.29$0.24
Q2 20173$0.22$0.24$0.23
Q3 20173$0.29$0.31$0.30
Q4 20172$0.32$0.32$0.32
Q1 20183$0.40$0.43$0.41
Q2 20183$0.32$0.38$0.35
Q3 20183$0.46$0.50$0.48
Q4 20183$0.50$0.61$0.55
Q1 20192$0.58$0.61$0.60
Q2 20191$0.51$0.51$0.51
Q3 20191$0.63$0.63$0.63
Q4 20192$0.65$0.82$0.74
(Data provided by Zacks Investment Research)


Dividend History for ABIOMED (NASDAQ:ABMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ABIOMED (NASDAQ:ABMD)
Insider Ownership Percentage: 7.00%
Institutional Ownership Percentage: 89.37%
Insider Trades by Quarter for ABIOMED (NASDAQ:ABMD)
Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)
Insider Trades by Quarter for ABIOMED (NASDAQ:ABMD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017Andrew J GreenfieldVPSell11,282$169.32$1,910,268.24View SEC Filing  
8/30/2017Eric A Md RoseDirectorSell982$145.17$142,556.94View SEC Filing  
8/24/2017Eric A Md RoseDirectorSell23,018$151.09$3,477,789.62View SEC Filing  
8/15/2017Paul ThomasDirectorSell10,000$154.71$1,547,100.00View SEC Filing  
7/31/2017David M WeberCOOSell16,500$147.63$2,435,895.00View SEC Filing  
5/16/2017Michael G HowleyVPSell18,279$133.56$2,441,343.24View SEC Filing  
5/8/2017David M WeberCOOSell21,250$130.89$2,781,412.50View SEC Filing  
5/8/2017Dorothy E PuhyDirectorSell13,500$131.12$1,770,120.00View SEC Filing  
5/8/2017Michael G HowleyVPSell600$132.84$79,704.00View SEC Filing  
3/17/2017Andrew J GreenfieldVPSell10,000$124.00$1,240,000.00View SEC Filing  
12/13/2016Dorothy E PuhyDirectorSell8,000$120.00$960,000.00View SEC Filing  
11/30/2016Eric A Md RoseDirectorSell8,000$110.81$886,480.00View SEC Filing  
9/22/2016Michael R MinogueCEOSell28,039$127.07$3,562,915.73View SEC Filing  
9/21/2016Michael R MinogueCEOSell5,034$127.07$639,670.38View SEC Filing  
9/19/2016Michael R MinogueCEOSell58,710$127.00$7,456,170.00View SEC Filing  
8/15/2016Dorothy E PuhyDirectorSell5,160$123.94$639,530.40View SEC Filing  
8/10/2016Dorothy E PuhyDirectorSell3,900$122.31$477,009.00View SEC Filing  
8/8/2016Michael G HowleyVPSell17,853$119.20$2,128,077.60View SEC Filing  
8/1/2016Henri A TermeerDirectorSell25,866$118.70$3,070,294.20View SEC Filing  
6/29/2016Michael G HowleyVPSell10,000$106.58$1,065,800.00View SEC Filing  
6/7/2016Andrew J GreenfieldVPSell9,000$104.16$937,440.00View SEC Filing  
5/23/2016David M WeberCOOSell4,342$96.97$421,043.74View SEC Filing  
5/16/2016David M WeberCOOSell5,604$94.56$529,914.24View SEC Filing  
5/6/2016David M WeberCOOSell2,145$93.82$201,243.90View SEC Filing  
5/5/2016David M WeberCOOSell52,000$95.27$4,954,040.00View SEC Filing  
5/5/2016Paul ThomasDirectorSell7,500$95.14$713,550.00View SEC Filing  
4/18/2016Andrew J GreenfieldVPSell10,000$99.10$991,000.00View SEC Filing  
4/13/2016Michael G HowleyVPSell9,800$98.64$966,672.00View SEC Filing  
4/8/2016Michael G HowleyVPSell200$98.80$19,760.00View SEC Filing  
4/1/2016Dorothy E PuhyDirectorSell10,000$95.02$950,200.00View SEC Filing  
3/31/2016Andrew J GreenfieldVPSell15,000$94.11$1,411,650.00View SEC Filing  
3/24/2016David M WeberCOOSell5,235$89.93$470,783.55View SEC Filing  
3/22/2016Andrew J GreenfieldVPSell24,800$89.06$2,208,688.00View SEC Filing  
3/22/2016Dorothy E PuhyDirectorSell10,000$90.30$903,000.00View SEC Filing  
3/21/2016Andrew J GreenfieldVPSell19,572$89.07$1,743,278.04View SEC Filing  
3/10/2016Andrew J GreenfieldVPSell200$89.00$17,800.00View SEC Filing  
3/8/2016David M WeberCOOSell17,521$85.20$1,492,789.20View SEC Filing  
3/8/2016William J BoltSVPSell17,510$85.19$1,491,676.90View SEC Filing  
3/7/2016David M WeberCOOSell8,111$85.21$691,138.31View SEC Filing  
3/7/2016Dorothy E PuhyDirectorSell4,000$85.00$340,000.00View SEC Filing  
3/7/2016William J BoltSVPSell7,987$85.20$680,492.40View SEC Filing  
2/8/2016Dorothy E. PuhyDirectorSell4,000$80.47$321,880.00View SEC Filing  
8/19/2015Michael R. MinogueCEOSell146,800$104.87$15,394,916.00View SEC Filing  
8/17/2015Dorothy E PuhyDirectorSell2,580$103.91$268,087.80View SEC Filing  
8/14/2015Dorothy E PuhyDirectorSell2,580$105.27$271,596.60View SEC Filing  
7/17/2015Michael G HowleyVPSell21,295$70.00$1,490,650.00View SEC Filing  
6/15/2015Andrew J GreenfieldVPSell3,185$65.00$207,025.00View SEC Filing  
5/29/2015Martin P SutterDirectorBuy7,500$60.17$451,275.00View SEC Filing  
5/27/2015David M WeberCOOSell17,968$60.77$1,091,915.36View SEC Filing  
5/12/2015Michael G HowleyVPSell17,353$66.47$1,153,453.91View SEC Filing  
5/7/2015Andrew J GreenfieldVPSell3,500$71.00$248,500.00View SEC Filing  
5/7/2015Robert BowenCFOSell2,372$71.52$169,645.44View SEC Filing  
5/6/2015David M WeberCOOSell1,605$73.72$118,320.60View SEC Filing  
5/6/2015Michael R MinogueCEOSell8,840$73.12$646,380.80View SEC Filing  
5/6/2015William J BoltSVPSell1,750$74.27$129,972.50View SEC Filing  
3/23/2015David M WeberCOOSell3,765$71.08$267,616.20View SEC Filing  
10/31/2014Andrew J GreenfieldVPSell15,000$31.90$478,500.00View SEC Filing  
10/31/2014Michael R MinogueCEOSell164,000$31.14$5,106,960.00View SEC Filing  
7/28/2014Michael R MinogueCEOSell82,383$26.30$2,166,672.90View SEC Filing  
5/27/2014Andrew J GreenfieldVPSell7,026$21.10$148,248.60View SEC Filing  
5/27/2014David M WeberCOOSell10,172$21.11$214,730.92View SEC Filing  
5/27/2014Michael R MinogueCEOSell90,001$21.19$1,907,121.19View SEC Filing  
5/27/2014Robert BowenCFOSell6,820$21.11$143,970.20View SEC Filing  
5/27/2014William J BoltSVPSell8,029$21.10$169,411.90View SEC Filing  
5/15/2014David WeberCOOSell1,425$20.94$29,839.50View SEC Filing  
5/15/2014Michael HowleyVPSell1,267$20.94$26,530.98View SEC Filing  
5/15/2014Michael MinogueCEOSell4,433$20.94$92,827.02View SEC Filing  
5/15/2014William BoltSVPSell1,110$20.94$23,243.40View SEC Filing  
1/10/2014Robert BowenCFOSell37,500$30.00$1,125,000.00View SEC Filing  
9/3/2013David WeberCOOSell6,500$24.00$156,000.00View SEC Filing  
9/3/2013William BoltSVPSell20,000$24.00$480,000.00View SEC Filing  
8/14/2013William BoltSVPSell21,534$23.35$502,818.90View SEC Filing  
8/13/2013David WeberCOOSell4,400$23.00$101,200.00View SEC Filing  
8/13/2013Michael HowleyVPSell8,400$23.00$193,200.00View SEC Filing  
8/5/2013David WeberCOOSell7,100$22.90$162,590.00View SEC Filing  
8/5/2013Michael HowleyVPSell1,600$23.03$36,848.00View SEC Filing  
8/5/2013Robert BowenCFOSell2,235$22.64$50,600.40View SEC Filing  
8/5/2013W Gerald AustenDirectorSell8,000$22.85$182,800.00View SEC Filing  
8/5/2013William BoltSVPSell20,166$22.70$457,768.20View SEC Filing  
7/31/2013Michael R MinogueCEOSell36,500$25.04$913,960.00View SEC Filing  
7/17/2013Michael G HowleyVPSell10,000$24.45$244,500.00View SEC Filing  
7/15/2013Robert BowenCFOSell40,786$23.50$958,471.00View SEC Filing  
7/11/2013Robert BowenCFOSell1,499$23.50$35,226.50View SEC Filing  
6/4/2013David M WeberCOOSell6,519$21.20$138,202.80View SEC Filing  
6/4/2013Michael G HowleyVPSell3,881$21.20$82,277.20View SEC Filing  
6/4/2013Michael R MinogueCEOSell17,667$21.23$375,070.41View SEC Filing  
6/4/2013Robert BowenCFOSell5,298$21.20$112,317.60View SEC Filing  
6/4/2013William J BoltSVPSell4,967$21.20$105,300.40View SEC Filing  
5/29/2013Michael R MinogueCEOSell58,833$21.83$1,284,324.39View SEC Filing  
5/28/2013David M WeberCOOSell6,018$22.18$133,479.24View SEC Filing  
5/28/2013Michael G HowleyVPSell5,476$22.18$121,457.68View SEC Filing  
5/28/2013Robert BowenCFOSell5,102$22.18$113,162.36View SEC Filing  
5/28/2013William J BoltSVPSell4,629$22.18$102,671.22View SEC Filing  
5/23/2013Andrew J GreenfieldVPSell1,666$21.63$36,035.58View SEC Filing  
5/23/2013Michael R MinogueCEOSell5,666$21.62$122,498.92View SEC Filing  
5/17/2013Robert BowenCFOSell2,715$23.50$63,802.50View SEC Filing  
5/9/2013Michael R MinogueCEOSell20,000$21.00$420,000.00View SEC Filing  
5/7/2013Henri A TermeerDirectorBuy100,000$19.86$1,986,000.00View SEC Filing  
2/25/2013Henri A TermeerDirectorBuy100,000$14.98$1,498,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for ABIOMED (NASDAQ:ABMD)
Latest Headlines for ABIOMED (NASDAQ:ABMD)
americanbankingnews.com logoABIOMED, Inc. (ABMD) Downgraded by BTIG Research to "Neutral"
www.americanbankingnews.com - October 16 at 8:20 AM
americanbankingnews.com logoFinancial Analysis: ABIOMED (ABMD) & Its Peers
www.americanbankingnews.com - October 15 at 2:10 AM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Receives "Outperform" Rating from Leerink Swann
www.americanbankingnews.com - October 15 at 12:34 AM
finance.yahoo.com logoSmith & Nephew Shows Improved Relative Price Performance; Still Shy Of Benchmark
finance.yahoo.com - October 11 at 3:35 PM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Downgraded by Zacks Investment Research
www.americanbankingnews.com - October 10 at 11:26 PM
finance.yahoo.com logoAbiomed Second Quarter Fiscal 2018 Earnings and Conference Call Notification
finance.yahoo.com - October 10 at 3:30 PM
americanbankingnews.com logoHead to Head Survey: ABIOMED (ABMD) vs. Hansen Medical (HNSN)
www.americanbankingnews.com - October 9 at 10:14 AM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 7 at 8:50 AM
americanbankingnews.com logoContrasting ABIOMED (ABMD) & The Competition
www.americanbankingnews.com - October 4 at 8:30 PM
americanbankingnews.com logoInsider Selling: ABIOMED, Inc. (ABMD) VP Sells 11,282 Shares of Stock
www.americanbankingnews.com - October 4 at 7:20 PM
rttnews.com logoAbiomed Inc. (ABMD) Rose To A New High For The Year
www.rttnews.com - October 2 at 3:12 PM
nasdaq.com logoFirst Week of November 17th Options Trading For ABIOMED (ABMD)
www.nasdaq.com - October 2 at 3:12 PM
finance.yahoo.com logo[$$] Funding Snapshot: Israel's Magenta Medical Secures $15 Million Series B for Heart-Failure Therapy
finance.yahoo.com - October 2 at 3:12 PM
americanbankingnews.com logoFY2019 EPS Estimates for ABIOMED, Inc. Reduced by Analyst (ABMD)
www.americanbankingnews.com - October 2 at 11:36 AM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Expected to Post Earnings of $0.37 Per Share
www.americanbankingnews.com - September 30 at 2:22 PM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Given New $208.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - September 29 at 12:16 PM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Coverage Initiated at SunTrust Banks, Inc.
www.americanbankingnews.com - September 29 at 10:02 AM
nasdaq.com logoAbiomed's Latest Regulatory Progress Boosts Impella Line - Nasdaq
www.nasdaq.com - September 28 at 1:44 AM
americanbankingnews.com logoLeMaitre Vascular (LMAT) vs. ABIOMED (ABMD) Head to Head Analysis
www.americanbankingnews.com - September 27 at 4:32 PM
americanbankingnews.com logoMindray Medical International (MR) vs. ABIOMED (ABMD) Financial Review
www.americanbankingnews.com - September 23 at 4:22 AM
seekingalpha.com logoStock Exchange: Climbing The Wall Of Worry - Seeking Alpha
seekingalpha.com - September 22 at 3:03 PM
finanznachrichten.de logoAbiomed: Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure
www.finanznachrichten.de - September 22 at 12:19 PM
americanbankingnews.com logoHead-To-Head Review: ABIOMED (ABMD) and Its Rivals
www.americanbankingnews.com - September 22 at 10:30 AM
seekingalpha.com logoAbiomed receives FDA PMA approval for Impella RP for right heart failure; shares ahead 2% premarket
seekingalpha.com - September 21 at 8:53 AM
globenewswire.com logoAbiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure - GlobeNewswire (press release)
globenewswire.com - September 21 at 1:26 AM
nasdaq.com logoFDA Nod For ABMD, AERI Faces FDA Panel In Oct, IPCI Put On Notice, PFE Sues JNJ - Nasdaq
www.nasdaq.com - September 21 at 1:26 AM
streetinsider.com logoAbiomed (ABMD) Announces FDA PMA Approval for Impella RP for Right Heart Failure - StreetInsider.com
www.streetinsider.com - September 20 at 8:24 PM
finance.yahoo.com logoAbiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure
finance.yahoo.com - September 20 at 8:24 PM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 12 at 9:03 AM
americanbankingnews.com logo$0.37 Earnings Per Share Expected for ABIOMED, Inc. (ABMD) This Quarter
www.americanbankingnews.com - September 11 at 8:16 PM
nasdaq.com logoABMD Crosses Above Average Analyst Target
www.nasdaq.com - September 11 at 3:47 PM
americanbankingnews.com logoBiolase (BIOL) vs. ABIOMED (ABMD) Head-To-Head Contrast
www.americanbankingnews.com - September 2 at 4:10 PM
finance.yahoo.com logoABIOMED, Inc. – Value Analysis (NASDAQ:ABMD) : September 2, 2017
finance.yahoo.com - September 2 at 1:54 AM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Director Eric A. Md Rose Sells 982 Shares
www.americanbankingnews.com - September 1 at 8:30 PM
americanbankingnews.com logoHarvard Bioscience (HBIO) & ABIOMED (ABMD) Critical Contrast
www.americanbankingnews.com - August 30 at 4:26 PM
finance.yahoo.com logoABIOMED, Inc. breached its 50 day moving average in a Bearish Manner : ABMD-US : August 30, 2017
finance.yahoo.com - August 30 at 3:21 PM
americanbankingnews.com logoABIOMED's (ABMD) Buy Rating Reiterated at Piper Jaffray Companies
www.americanbankingnews.com - August 30 at 2:28 PM
marketwatch.com logoAbiomed searches for new CFO after Tomsicek resigns - MarketWatch
www.marketwatch.com - August 30 at 1:49 AM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - August 29 at 1:04 PM
streetinsider.com logoAbiomed (ABMD) CFO Resigns to Pursue Other Interests
www.streetinsider.com - August 29 at 1:38 AM
streetinsider.com logoAbiomed (ABMD) CFO Resigns to Pursue Other Interests - StreetInsider.com
www.streetinsider.com - August 28 at 8:37 PM
finance.yahoo.com logoAbiomed Announces Resignation of Chief Financial Officer and Welcomes Back Former Chief Financial Officer as Consultant
finance.yahoo.com - August 28 at 8:37 PM
finance.yahoo.com logoAbiomed searches for new CFO after Tomsicek resigns
finance.yahoo.com - August 28 at 8:37 PM
americanbankingnews.com logoEric A. Md Rose Sells 23,018 Shares of ABIOMED, Inc. (ABMD) Stock
www.americanbankingnews.com - August 28 at 7:20 PM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Expected to Post Quarterly Sales of $130.37 Million
www.americanbankingnews.com - August 26 at 4:00 PM
americanbankingnews.com logoHead to Head Survey: ABIOMED (ABMD) vs. PerkinElmer (PKI)
www.americanbankingnews.com - August 25 at 10:36 AM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 18 at 8:38 AM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Director Sells $1,547,100.00 in Stock
www.americanbankingnews.com - August 17 at 7:38 PM
finance.yahoo.com logoETFs with exposure to ABIOMED, Inc. : August 15, 2017
finance.yahoo.com - August 15 at 3:35 PM
finance.yahoo.com logoIHS Markit Score Update: Drop in demand for ETFs holding Abiomed Inc is a negative sign for its shares
finance.yahoo.com - August 12 at 1:41 AM



ABIOMED (ABMD) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.